Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Principal criteria for evaluating the quality, safety and efficacy of hMSC-based products in clinical practice: Current approaches and challenges

  • Guadix, Juan Antonio
  • López-Beas, Javier
  • Clares Naveros, Beatriz
  • Soriano-Ruiz, José Luis
  • Zugaza, José L.
  • Gálvez Martín, Patricia
Human Mesenchymal Stem Cells (hMSCs) play an important role as new therapeutic alternatives in advanced therapies and regenerative medicine thanks to their regenerative and immunomodulatory properties, and ability to migrate to the exact area of injury. These properties have made hMSCs one of the more promising cellular active substances at present, particularly in terms of the development of new and innovative hMSC-based products. Currently, numerous clinical trials are being conducted to evaluate the therapeutic activity of hMSC-based products on specific targets. Given the rapidly growing number of hMSC clinical trials in recent years and the complexity of these products due to their cellular component characteristics and medicinal product status, there is a greater need to define more stringent, specific, and harmonized requirements to characterize the quality of the hMSCs and enhance the analysis of their safety and efficacy in final products to be administered to patients. These requirements should be implemented throughout the manufacturing process to guarantee the function and integrity of hMSCs and to ensure that the hMSC-based final product consistently meets its specifications across batches. This paper describes the principal phases involved in the design of the manufacturing process and updates the specific technical requirements needed to address the appropriate clinical use of hMSC-based products. The challenges and limitations to evaluating the safety, efficacy, and quality of hMSCs have been also reviewed and discussed., This work was supported by Ministerio de Ciencia, Innovación y Universidades. Plan Estatal I+D+I, Grant Number: RTI2018-095410-B-100; Spanish Ministry of Economy (MINECO), Grant Number: RD16/0011/0030; Spanish Ministry of Science, Innovation and Universities (to JAG) and by the Ministerio de Economía, Industria y Competitividad (FEDER funds, project RTC-2016-5451-1) (to BC and PG-M). Additional it has been developed in the context of AdvanceCat with the support of ACCIÓ (Catalonia Trade & Investment; Generalitat de Catalunya) under the Catalonian European Regional Development Fund operational program, 2014-2020 (to PG-M).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

An overview of international regulatory frameworks for mesenchymal stromal cell‐based medicinal products: From laboratory to patient

  • López-Beas, Javier
  • Guadix, Juan Antonio
  • Clares Naveros, Beatriz
  • Soriano-Ruiz, José Luis
  • Zugaza, José L.
  • Gálvez Martín, Patricia
Human mesenchymal stromal cells (hMSCs) are emerging as one of the most important cell types in advanced therapies and regenerative medicine due to their great therapeutic potential. The development of hMSC‐based products focuses on the use of hMSCs as biological active substances, and they are considered medicinal products by the primary health agencies worldwide. Due to their regulatory status, the development of hMSC‐based products is regulated by specific criteria that range from the design phase, nonclinical studies, clinical studies, to the final registration and approval. Patients should only be administered hMSC‐based products within the framework of a clinical trial or after the product has obtained marketing authorization; in both cases, authorization by health authorities is usually required. Considering the above, this paper describes the current general regulatory requirements for hMSC‐based products, by jurisdiction, to be implemented throughout their entire development process. These measures may provide support for researchers from both public and private entities and academia to optimize the development of these products and their subsequent marketing, thereby improving access to them by patients., This study was supported by the Spanish Ministry of Science, Innovation and Universities (MICIU), State Plan for Scientific and Technical Research and Innovation, Grant/Award No: RTI2018‐095410‐BI00; Spanish Ministry of Economy, Industry and Competitiveness (MINECO), Grant/Award No: RD16/0011/0030; MICIU (to JAG) and MINECO (FEDER funds, project RTC‐2016‐5451‐1) (to BC and PG‐M). Furthermore, this study has been also developed in the context of AdvanceCat with the support of ACCIÓ (Catalonia Trade & Investment; Generalitat de Catalunya) under the Catalonian European Regional Development Fund operational program, 2014 to 2020 (to PG‐M)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Self-Assembled type I collagen-apatite fibers with varying mineralization extent and luminescent terbium promote osteogenic differentiation of mesenchymal stem cells

  • Romero-Castillo, Ismael
  • López-Ruiz, Elena
  • Fernández-Sánchez, Jorge F.
  • Marchal-Corrales, Juan Antonio
  • Gómez-Morales, Jaime
This work explores in depth the simultaneous self¿assembly and mineralization of type I collagen by a base¿acid neutralization technique to prepare biomimetic collagen¿apatite fibrils with varying mineralization extent and doped with luminescent bactericidal Tb3+ ions. Two variants of the method are tested: base¿acid titration, a solution of Ca(OH)2 is added dropwise to a stirred solution containing type I collagen dispersed in H3PO4; and direct mixing, the Ca(OH)2 solution is added by fast dripping onto the acidic solution. Only the direct mixing variant yielded an effective control of calcium phosphate polymorphism. Luminescence spectroscopy reveals the long luminescence lifetime and high relative luminescence intensity of the Tb3+¿doped materials, while two¿photon confocal fluorescence microscopy shows the characteristic green fluorescence light when using excitation wavelength of 458 nm, which is not harmful to bone tissue. Cytotoxicity/viability tests reveal that direct mixing samples show higher cell proliferation than titration samples. Additionally, osteogenic differentiation essays show that all mineralized fibrils promote the osteogenic differentiation, but the effect is more pronounced when using samples prepared by direct mixing, and more notably when using the Tb3+¿doped mineralized fibrils. Based on these findings it is concluded that the new nanocomposite is an ideal candidate for bone regenerative therapy., This work was funded by the Ministerio de Ciencia, Innovación y Universidades, co‐funded by FEDER (Project Nos. PGC2018‐102047‐B‐I00 and RTC‐2016‐5451‐1) and by Fundación Mutua Madrileña (Project No. FMM‐AP17196‐2019). The authors also acknowledge technicians of VPSEM, TEM, and confocal microscopy of CIC of University of Granada for their valuable support.